Anaptysbio, Inc.

Medarex Inc.

Atyr Pharma, Inc.

Ucb Pharma, S.a.

Momenta Pharmaceuticals, Inc.

E. R. Squibb Sons, Inc.

University of Massachusetts

Corixa Corporation

Tesaro, Inc.

Lassen Therapeutics, Inc.

Other

Ucb Celltech

Celltech Chiroscience Limited

Lassen Therapeutics 1, Inc.

David J King

Marilyn Kehry

Josephine M Cardarelli

Robert A Horlick

David B Passmore

Alison Witte

Peter M Bowers

Andrew John McKnight

Christopher Robert Bebbington

Denise Leah Williams

Andrew Paul Chapman

Andrew George Popplewell

Derek Thomas Brown

Luke Burman

Helen Toni Jun

Andrew Neil Charles Weir

Howard P Ng

Guoxian Wu

Francis J Carr

Oliver L Saunders

Diljeet Singh Athwal

Thomas Jay Lobl

Sarah Lee Pogue

Leona E Ling

James Meador, Iii

Stephen Williams

Chetana Rao-Naik

Dawn M Tanamachi

Sucharita Roy

Valeri Martichonok

Danny P C McGee

Tseng-hui Timothy Chen

Anthony Manning

Sharon Elaine Boyd

Marco Londei

Haichun Huang

Leslie Ann Greene

Jie Liu

Gary R Fanger

Marc W Retter

Geoffrey T Yarranton

Heidi N Leblanc

Kenneth L Rock

Kristopher Toy

Chin Pan

Mark Yamanaka

Ryan Andrew Adams

Richard Theolis

Lesley B Pickford

Zhiwen Xu

Kyra D Zens

Zhi-Hong Li

Tim Sproul

Neil Fanger

Asna Masood

Sarah R Reed

Tamlyn Yee Neben

Jean Da Silva Correia

Leslie Nangle Greene

Liting Zhai

Kaitlyn Rauch

Ann Menefee

Kristina Hamel

Yanyan Geng

Yee Ting (Esther) Chong

Baochuan Huang

Yeeting Chong

Sanjeev Gangwar

Irina Astafieva

Jimmie L Moore

Zhihong Li

Nathaniel J Washburn

Li-Sheng Lu

Xue Zhang

Alasdair Fraser Bell

Deborah A Witherden

Christine M Chidester

Magdalena S Willen

Mark G Barrett

Peter Bowers

Srimoyee Ghosh

Betty Wu

Dilijeet Singh Athwal

Sharline Chen

To Uyen Thi Do

Jonathan Alexander Terret

Josphine M Cardelli

Audrey McConnell

Laurence Altobell, Iii

Traci Roberts

Jennifer Dalton

Jan Hillson

Danny P Mcgee

Geoffrey Thomas Yarranton

James Iii Meador

Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Compositions comprising anti-NRP2 antibodies

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Antibodies directed against interleukin 36 receptor (IL-36R)

Provided are antibodies that bind to interleukin-18 binding protein (IL-18BP) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers and other diseases.

Anti-IL-18BP antibodies

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

Method of treating an interleukin-11-associated or -mediated fibrotic disease or condition by administering an anti-interleukin-11 receptor subunit alpha (IL-11RA) antibody

Anti-interleukin-11 receptor subunit α (IL-11Rα) antibodies

Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

Compositions and methods comprising anti-NRP2 antibodies

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.

Method of treating autoimmune disease with antibodies against IL-33

Therapeutic compositions comprising anti-NRP2 antibodies

Provided herein are anti-T Cell Immunoglobulin and Mucin Protein-3 (TIM 3) antibodies having particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences and methods of using the anti-TIM-3 antibodies to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)

The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.

FcRn antibodies and methods of use thereof

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (TIM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.

Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.

Antibodies directed against programmed death-1 (PD-1)

Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)

Growing community of inventors

Encinitas, CA, United States of America

David J King